Skip to main content

Articles

Page 13 of 17

  2. In clinical trials new oral anticoagulants (NOAC) have proved to be as effective as warfarin for thromboprophylaxis in atrial fibrillation. The aim of this study was to evaluate the efficacy and safety of thes...

    Authors: Ashkan Labaf, Martin Carlwe and Peter J Svensson
    Citation: Thrombosis Journal 2014 12:29
    Content type: Original clinical investigation Published on:

  3. Venous thromboembolism (VTE) requires urgent diagnosis and treatment to avoid related complications. Clinical presentations of VTE are nonspecific and require definitive confirmation by imaging techniques. A c...

    Authors: Tarek Owaidah, Nahlah AlGhasham, Saad AlGhamdi, Dania AlKhafaji, Bandar ALAmro, Mohamed Zeitouni, Fawaz Skaff, Hazzaa AlZahrani, Adher AlSayed, Naser ElKum, Mahmoud Moawad, Ahmed Nasmi, Mohannad Hawari and Khalid Maghrabi
    Citation: Thrombosis Journal 2014 12:28
    Content type: Original clinical investigation Published on:

  4. Statins may reduce the risk of first and recurrent venous thromboembolism (VTE). No data are available on their potential benefit in patients treated with the oral anticoagulant rivaroxaban.

    Authors: Philip S Wells, Martin Gebel, Martin H Prins, Bruce L Davidson and Anthonie WA Lensing
    Citation: Thrombosis Journal 2014 12:26
    Content type: Original clinical investigation Published on:

  5. Patients with renal impairment receiving classical anticoagulation for venous thromboembolism (VTE) are at increased risk of bleeding and possibly pulmonary embolism. We examined the efficacy and safety of ora...

    Authors: Rupert M Bauersachs, Anthonie WA Lensing, Martin H Prins, Dagmar Kubitza, Ákos F Pap, Hervé Decousus, Jan Beyer-Westendorf and Paolo Prandoni
    Citation: Thrombosis Journal 2014 12:25
    Content type: Original basic research Published on:

  6. Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment...

    Authors: Jonathan Douxfils, Anne Tamigniau, Bernard Chatelain, Catherine Goffinet, Jean-Michel Dogné and François Mullier
    Citation: Thrombosis Journal 2014 12:24
    Content type: Review Published on:

  8. Increasing age and renal impairment are risk factors for venous thrombosis but also for anticoagulant-induced bleeding. In large-scale phase III trials, non-VKA oral anticoagulants (NOACs) were at least as eff...

    Authors: Vincent Geldhof, Christophe Vandenbriele, Peter Verhamme and Thomas Vanassche
    Citation: Thrombosis Journal 2014 12:21
    Content type: Review Published on:

  9. Warfarin is known for its interaction with many drugs, resulting in undesired treatment outcomes such as bleeding. The study aimed to assess the prevalence of drug-drug interactions and determinants of bleedin...

    Authors: Gebrehiwot Teklay, Nuredin Shiferaw, Befikadu Legesse and Mebratu Legesse Bekele
    Citation: Thrombosis Journal 2014 12:20
    Content type: Original clinical investigation Published on:

  10. Enoxaparin displays fibrinolytic activity through stimulation of endothelial release of tissue plasminogen activator. Moreover, enoxaparin increases the release of tissue factor pathway inhibitor, which inhibi...

    Authors: Gesa Wiegand, Vanya Icheva, Martin Schöning and Michael Hofbeck
    Citation: Thrombosis Journal 2014 12:19
    Content type: Case report Published on:

  11. Erythropoietin (Epo) has been shown to improve myocardial function in models of experimental myocardial infarction, but has also been associated with a rise in thromboembolic events. Thus, the aim of this stud...

    Authors: Gabriele Demetz, Magdalena Laux, Armin Scherhag, Tiny Hoekstra, Marit M Suttorp, Friedo Dekker, Mark Roest, Mira Marcus-Kalish, Moshe Mittelman and Ilka Ott
    Citation: Thrombosis Journal 2014 12:18
    Content type: Original clinical investigation Published on:

  12. To evaluate the association between angiotensin I-converting enzyme insertion/deletion (ACE I/D) gene polymorphism and retinal vein occlusion (RVO). A total of 80 patients with retinal vein occlusion who was a...

    Authors: Işıl Kutluturk, Ali Karagöz, Tahir Bezgin, Vecih Oduncu, Ali Elveran, Cem Doğan, Ahmet Elbay, Cevat Kirma and Yusuf Özertürk
    Citation: Thrombosis Journal 2014 12:17
    Content type: Original clinical investigation Published on:

  13. Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related diseases remains high. Anticoagulati...

    Authors: Walter Ageno, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Verena Haupt, Jonas Schneider and Alexander GG Turpie
    Citation: Thrombosis Journal 2014 12:16
    Content type: Original clinical investigation Published on:

  14. Venous thromboembolic disease (VTE) is associated with high morbi-mortality. Adherence rate to the recommendations of antithrombotic prophylaxis guidelines (ATPG) is suboptimal. The aim of this study was to de...

    Authors: Fernando Vazquez, Ricardo Watman, Aldo Tabares, Carina Gumpel, Enrique Baldessari, Alicia B Vilaseca, Federico J Capparelli and Esteban Lifschitz
    Citation: Thrombosis Journal 2014 12:15
    Content type: Original clinical investigation Published on:

  15. Atrial fibrillation (AF) patients frequently require anticoagulation with vitamin K antagonists (VKAs) to prevent thromboembolic events, but their use increases the risk of hemorrhage. We evaluated time spent ...

    Authors: Elizabeth S Mearns, C Michael White, Christine G Kohn, Jessica Hawthorne, Ju-Sung Song, Joy Meng, Jeff R Schein, Monika K Raut and Craig I Coleman
    Citation: Thrombosis Journal 2014 12:14
    Content type: Original clinical investigation Published on:

  16. Atrial fibrillation (AF) is a common cardiac arrhythmia, and leading cause of ischemic stroke. Despite proven effectiveness, warfarin remains an under-used treatment in atrial fibrillation patients. We sought ...

    Authors: Stuart G Nicholls, Jamie C Brehaut, Rubab G Arim, Kelly Carroll, Richard Perez, Kaveh G Shojania, Jeremy M Grimshaw and Roy M Poses
    Citation: Thrombosis Journal 2014 12:13
    Content type: Original clinical investigation Published on:

  18. Deep venous thrombosis (DVT), which is often associated with pulmonary embolism (PE), is a serious complication after total knee arthroplasty (TKA). In the present study, we examined the overall thrombotic and...

    Authors: Yukinori Tamura, Shigeshi Mori, Shigeki Asada, Naoyuki Kawao, Shigeru Ueshima, Hiroshi Kaji, Junichiro Yamamoto, Masao Akagi and Osamu Matsuo
    Citation: Thrombosis Journal 2014 12:11
    Content type: Original clinical investigation Published on:

  19. Platelet inhibitors are commonly used to reduce the risk of atherothrombotic events. The aim of this study was to determine the impact of platelet inhibitors, specifically clopidogrel and aspirin, on clot kine...

    Authors: Joseph F Dwyer, Jill A McCoy, Ziping Yang, Michael Husser, Heinz Redl, Mary Ann Murphy, Martin Wolfsegger, James P DiOrio, Andreas Goppelt and Shane Donovan
    Citation: Thrombosis Journal 2014 12:10
    Content type: Original basic research Published on:

  20. Venous thromboembolism (VTE) prophylaxis is underutilized for hospitalized patients. The primary objective of this study was to assess the impact of a continuing medical education (CME) program on thromboproph...

    Authors: Fahad Al-Hameed, Hasan M Al-Dorzi and Essam Aboelnazer
    Citation: Thrombosis Journal 2014 12:9
    Content type: Original clinical investigation Published on:

  22. New oral anticoagulant (NOAC) drugs are known to influence the results of some routine hemostasis tests. Further data are needed to enable routine assessment of the effects of NOAC on clotting parameters in so...

    Authors: Raul Altman and Claudio Daniel Gonzalez
    Citation: Thrombosis Journal 2014 12:7
    Content type: Original clinical investigation Published on:

  25. Thromboelastography® (TEG) utilizes kaolin, an intrinsic pathway activator, to assess clotting function. Recent published studies suggest that TEG results are commonly normal in patients receiving warfarin, de...

    Authors: C Michael Dunham, Charlene Rabel, Barbara M Hileman, Jason Schiraldi, Elisha A Chance, Mark T Shima, Alddo A Molinar and David A Hoffman
    Citation: Thrombosis Journal 2014 12:4
    Content type: Original clinical investigation Published on:

  27. The Editors of Thrombosis Journal would like to thank all our reviewers who have contributed to the journal in Volume 11 (2013).

    Authors: Yukio Ozaki and Hugo ten Cate
    Citation: Thrombosis Journal 2014 12:2
    Content type: Reviewer acknowledgement Published on:

  28. Paxillin is a LIM domain protein localized at integrin-mediated focal adhesions. Although paxillin is thought to modulate the functions of integrins, little is known about the contribution of paxillin to signa...

    Authors: Asuka Sakata, Tsukasa Ohmori, Satoshi Nishimura, Hidenori Suzuki, Seiji Madoiwa, Jun Mimuro, Kazuomi Kario and Yoichi Sakata
    Citation: Thrombosis Journal 2014 12:1
    Content type: Original basic research Published on:

  29. Atrial fibrillation (AF) is a common tachyarrhythmia in Australia, with a prevalence over 10% in older patients. AF is the leading preventable cause of ischaemic stroke, and strokes due to AF have a higher mor...

    Authors: Christopher Ward, Greg Conner, Geoffrey Donnan, Alexander Gallus and Simon McRae
    Citation: Thrombosis Journal 2013 11:27
    Content type: Review Published on:

  30. Left atrial appendage (LAA) thrombosis is an important cause of cardiogenic cerebral thromboembolism. Apixaban is a member of the class of novel oral anticoagulants (NOAC) and is superior to warfarin in preven...

    Authors: Tohru Kawakami, Hiroko Kobayakawa, Hiroyoshi Ohno, Nobukiyo Tanaka and Hiroki Ishihara
    Citation: Thrombosis Journal 2013 11:26
    Content type: Case report Published on:

  31. The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized 8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) and, for the first time in trials in this setting, i...

    Authors: Yuqi Wang, Chen Wang, Zhong Chen, Jiwei Zhang, Zhihong Liu, Bi Jin, Kejing Ying, Changwei Liu, Yuxia Shao, Zhicheng Jing, Isabelle Ling Meng, Martin H Prins, Ákos F Pap, Katharina Müller and Anthonie WA Lensing
    Citation: Thrombosis Journal 2013 11:25
    Content type: Original clinical investigation Published on:

  32. Lupus anticoagulant (LA) is known to inhibit thrombin generation although patients have an increased risk to develop thrombosis. We tried to determine whether thrombin generation is altered in plasma samples o...

    Authors: Klas Boeer, Leonid Cuznetov and Wolfgang Loesche
    Citation: Thrombosis Journal 2013 11:24
    Content type: Original basic research Published on:

  33. Platelets were activated under the infection with H. pylori in human and mice. We investigated the role of VacA, an exotoxin released by H. pylori in this context. Acid-activated VacA, but not heated VacA, induce...

    Authors: Kaneo Satoh, Toshiya Hirayama, Katsuhiro Takano, Katsue Suzuki-Inoue, Tadashi Sato, Masato Ohta, Junko Nakagomi and Yukio Ozaki
    Citation: Thrombosis Journal 2013 11:23
    Content type: Original basic research Published on:

  36. Plasma protein-C exerts anticoagulatory effects by inactivating factors V and VIII. Hereditary protein C deficiency is transmitted as an autosomal dominant disorder. Homozygous individuals usually develop purp...

    Authors: Syed Maqbool, Vishal Rastogi, Ashok Seth, Satbir Singh, Vijay Kumar and Arif Mustaqueem
    Citation: Thrombosis Journal 2013 11:19
    Content type: Case report Published on:

  37. Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for acute and extended treatment of symptomatic ...

    Authors: Martin H Prins, Anthonie WA Lensing, Rupert Bauersachs, Bonno van Bellen, Henri Bounameaux, Timothy A Brighton, Alexander T Cohen, Bruce L Davidson, Hervé Decousus, Gary E Raskob, Scott D Berkowitz and Philip S Wells
    Citation: Thrombosis Journal 2013 11:21
    Content type: Original clinical investigation Published on:

  38. Anticoagulation with vitamin K antagonists such as warfarin has historically been used for the long term management of patients with thromboembolic disease. However, these agents have a slow onset of action wh...

    Authors: Faryal Tahir, Haris Riaz, Talha Riaz, Maaz B Badshah, Irbaz B Riaz, Ameer Hamza and Hafsa Mohiuddin
    Citation: Thrombosis Journal 2013 11:18
    Content type: Review Published on:

  39. Behcet’s disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most fre...

    Authors: Hoda Abdel Badaee, Amr Edrees, Sherif Amin, Maher El Amir and Gaafar Ragab
    Citation: Thrombosis Journal 2013 11:17
    Content type: Original clinical investigation Published on:

  40. The incidence of venous thromboembolic disease (VTED) is estimated to be, on average, 1–2 cases per 1,000 individuals per year worldwide. There are few data concerning the incidence rate (IR) of VTED in the Ar...

    Authors: Fernando Javier Vázquez, María Lourdes Posadas-Martínez, Jimena Vicens, Fernán González Bernaldo de Quirós and Diego Hernán Giunta
    Citation: Thrombosis Journal 2013 11:16
    Content type: Original clinical investigation Published on:

  42. Atrial fibrillation (AF) is the most common form of heart arrhythmia and a leading cause of stroke and systemic embolism. Chronic anticoagulation is recommended for preventing those complications. Our study ai...

    Authors: Léon Nshimyumukiza, Julie Duplantie, Mathieu Gagnon, Xavier Douville, Diane Fournier, Carmen Lindsay, Marc Parent, Alain Milot, Yves Giguère, Christian Gagné, François Rousseau and Daniel Reinharz
    Citation: Thrombosis Journal 2013 11:14
    Content type: Original basic research Published on:

  43. Direct oral anticoagulants that target a single coagulation factor have been developed as an alternative to standard therapies with heparin and/or vitamin K antagonists. The purpose of this study was to derive...

    Authors: Martin H Prins and Anthonie WA Lensing
    Citation: Thrombosis Journal 2013 11:13
    Content type: Original clinical investigation Published on:

  44. Microplate-based thrombin generation test (TGT) is widely used as clinical measure of global hemostatic potential and it becomes a useful tool for control of drug potency and quality by drug manufactures. Howe...

    Authors: Yideng Liang, Samuel A Woodle, Alexey M Shibeko, Timothy K Lee and Mikhail V Ovanesov
    Citation: Thrombosis Journal 2013 11:12
    Content type: Original basic research Published on:

  45. Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of whic...

    Authors: Meyer Michel Samama, Geneviève Contant, Theodore E Spiro, Elisabeth Perzborn, Lena Le Flem, Céline Guinet, Yves Gourmelin, Gabriele Rohde and Jean-Luc Martinoli
    Citation: Thrombosis Journal 2013 11:11
    Content type: Review Published on:

  46. Unlike traditional anticoagulants, the more recently developed agents rivaroxaban, dabigatran and apixaban target specific factors in the coagulation cascade to attenuate thrombosis. Rivaroxaban and apixaban d...

    Authors: Wolfgang Mueck, Stephan Schwers and Jan Stampfuss
    Citation: Thrombosis Journal 2013 11:10
    Content type: Review Published on:

  50. While the assessment of analytical precision within medical laboratories has received much attention in scientific enquiry, the degree of as well as the sources causing variation between them remains incomplet...

    Authors: Michael Nagler, Lucas M Bachmann, Lorenzo Alberio, Anne Angelillo-Scherrer, Lars M Asmis, Wolfgang Korte, Adriana Mendez, Guido Reber, Hans Stricker, Dimitrios A Tsakiris and Walter A Wuillemin
    Citation: Thrombosis Journal 2013 11:6
    Content type: Original clinical investigation Published on:
Submit manuscript

Official journal of

  • APSTH logo

  • Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.6
    5-year Journal Impact Factor: 3.1
    Source Normalized Impact per Paper (SNIP): 0.653
    SCImago Journal Rank (SJR): 0.572

    Speed 2023
    Submission to first editorial decision (median days): 11
    Submission to acceptance (median days): 107

    Usage 2023
    Downloads: 708,004
    Altmetric mentions: 943

Thrombosis Journal

ISSN: 1477-9560

Contact us